DM1-SMe

DM1-SMe

• CAS Number: 138148-68-2
• UNSPSC Description: DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1].
• Target Antigen: ADC Cytotoxin; Microtubule/Tubulin
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/dm1-sme.html
• Purity: 98.16
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
• Molecular Weight: 784.38
• References & Citations: [1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. |[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, protect from light)
• Clinical Information: No Development Reported